RJ Kok
RJ Kok
Verified email at uu.nl - Homepage
Cited by
Cited by
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
K Temming, RM Schiffelers, G Molema, RJ Kok
Drug resistance updates 8 (6), 381-402, 2005
Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin
RM Schiffelers, GA Koning, TLM ten Hagen, MHAM Fens, AJ Schraa, ...
Journal of Controlled Release 91 (1-2), 115-122, 2003
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status
R van der Meel, LJC Vehmeijer, RJ Kok, G Storm, EVB van Gaal
Intracellular Delivery III, 163-200, 2016
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy
M Everts, V Saini, JL Leddon, RJ Kok, M Stoff-Khalili, MA Preuss, ...
Nano letters 6 (4), 587-591, 2006
Preparation and Functional Evaluation of RGD-Modified Proteins as αvβ3 Integrin Directed Therapeutics
RJ Kok, AJ Schraa, EJ Bos, HE Moorlag, SA Ásgeirsdóttir, M Everts, ...
Bioconjugate chemistry 13 (1), 128-135, 2002
Diverse origins of the myofibroblast—implications for kidney fibrosis
LL Falke, S Gholizadeh, R Goldschmeding, RJ Kok, TQ Nguyen
Nature Reviews Nephrology 11 (4), 233-244, 2015
Targeting tumors with nanobodies for cancer imaging and therapy
S Oliveira, R Heukers, J Sornkom, RJ Kok, PMPB en Henegouwen
Journal of Controlled Release 172 (3), 607-617, 2013
Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α-and IL-1β-induced proinflammatory status of endothelial cells in vitro
JM Kułdo, J Westra, SA Ásgeirsdóttir, RJ Kok, K Oosterhuis, MG Rots, ...
American Journal of Physiology-Cell Physiology 289 (5), C1229-C1239, 2005
Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate–containing RGD peptide liposomes inhibits experimental arthritis
GA Koning, RM Schiffelers, MHM Wauben, RJ Kok, E Mastrobattista, ...
Arthritis & Rheumatism 54 (4), 1198-1208, 2006
Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme
RJ Kok, F Grijpstra, RB Walthuis, F Moolenaar, D De Zeeuw, DKF Meijer
Journal of Pharmacology and Experimental Therapeutics 288 (1), 281-285, 1999
Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges
F Ramazani, W Chen, CF van Nostrum, G Storm, F Kiessling, T Lammers, ...
International journal of pharmaceutics 499 (1-2), 358-367, 2016
A Novel Strategy to Modify Adenovirus Tropism and Enhance Transgene Delivery to Activated Vascular Endothelial Cells In Vitro and In Vivo
K Ogawara, MG Rots, RJ Kok, HE Moorlag, AM Van Loenen, DKF Meijer, ...
Human gene therapy 15 (5), 433-443, 2004
Reduction of advanced liver fibrosis by short‐term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats
M Moreno, T Gonzalo, RJ Kok, P Sancho‐Bru, M Van Beuge, J Swart, ...
Hepatology 51 (3), 942-952, 2010
Peptide-targeted PEG-liposomes in anti-angiogenic therapy
A Janssen, RM Schiffelers, TLM Ten Hagen, GA Koning, AJ Schraa, ...
International journal of pharmaceutics 254 (1), 55-58, 2003
Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells
MEM Dolman, S Harmsen, G Storm, WE Hennink, RJ Kok
Advanced drug delivery reviews 62 (14), 1344-1357, 2010
Gold nanoparticles in theranostic oncology: current state-of-the-art
S Akhter, MZ Ahmad, FJ Ahmad, G Storm, RJ Kok
Expert opinion on drug delivery 9 (10), 1225-1243, 2012
Nanomedicines as cancer therapeutics: current status
S Akhter, I Ahmad, MZ Ahmad, F Ramazani, A Singh, Z Rahman, ...
Current cancer drug targets 13 (4), 362-378, 2013
Targeting podocyte-associated diseases
JW Leeuwis, TQ Nguyen, A Dendooven, RJ Kok, R Goldschmeding
Advanced drug delivery reviews 62 (14), 1325-1336, 2010
Oxidative stress in obstructive nephropathy
A Dendooven, DA Ishola Jr, TQ Nguyen, DM Van der Giezen, RJ Kok, ...
International journal of experimental pathology 92 (3), 202-210, 2011
Design, Synthesis, and Biological Evaluation of a Dual Tumor-specific Motive Containing Integrin-targeted Plasmin-cleavable Doxorubicin Prodrug 1 This work was partly supported …
FMH De Groot, HJ Broxterman, HPHM Adams, A Van Vliet, GI Tesser, ...
Molecular cancer therapeutics 1 (11), 901-911, 2002
The system can't perform the operation now. Try again later.
Articles 1–20